US20040071736A1 - Methods and compounds for the treatment of mucus hypersecretion - Google Patents

Methods and compounds for the treatment of mucus hypersecretion Download PDF

Info

Publication number
US20040071736A1
US20040071736A1 US10/633,698 US63369803A US2004071736A1 US 20040071736 A1 US20040071736 A1 US 20040071736A1 US 63369803 A US63369803 A US 63369803A US 2004071736 A1 US2004071736 A1 US 2004071736A1
Authority
US
United States
Prior art keywords
domain
translocating
translocating domain
chain
mucus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/633,698
Inventor
Conrad Quinn
Keith Foster
John Chaddock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntaxin Ltd
Original Assignee
Health Protection Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB9818548.1 priority Critical
Priority to GBGB9818548.1A priority patent/GB9818548D0/en
Priority to US09/763,669 priority patent/US6632440B1/en
Application filed by Health Protection Agency filed Critical Health Protection Agency
Priority to US10/633,698 priority patent/US20040071736A1/en
Assigned to HEALTH PROTECTION AGENCY reassignment HEALTH PROTECTION AGENCY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHADDOCK, JOHN, FOSTER, KEITH ALAN, QUINN, CONRAD PADRAIG
Publication of US20040071736A1 publication Critical patent/US20040071736A1/en
Priority claimed from US11/806,496 external-priority patent/US8790897B2/en
Assigned to SYNTAXIN LIMITED reassignment SYNTAXIN LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HEALTH PROTECTION AGENCY
Priority claimed from US12/101,749 external-priority patent/US20080249019A1/en
Application status is Abandoned legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Abstract

A method of treating mucus hypersecretion, the causative factor in chronic obstructive pulmonary disease (COPD), asthma and other clinical conditions involving COPD, comprises administering a compound that inhibits exocytosis in mucus secreting cells or neurones that control or direct mucus secretion. Also described is a compound, for use in the treatment of hypersecretion of mucus, which inhibits mucus secretion by inhibiting mucus secretion by mucus secreting cells, and/or inhibiting neurotransmitter release from neuronal cells controlling or directing mucus secretion.

Description

    BACKGROUND OF THE INVENTION
  • 1. Field of the Invention [0001]
  • The present invention relates to treatment of mucus hypersecretion, to compositions therefor and manufacture of those compositions. The present invention relates particularly, though not exclusively, to the treatment of chronic bronchitis in chronic obstructive pulmonary disease (COPD), asthma and other clinical conditions involving COPD. [0002]
  • 2. Description of Related Art [0003]
  • Mucus is a thin film of protective viscoelastic liquid which lines the airways. It is a 1-2% aqueous solution, in which the major components are the glycoconjugates known as mucins. Mucus, including the mucins, is secreted by mucus secretory cells, the surface epithelial goblet cells of the large airways and the mucus cells of the submucosal glands. Mucin release occurs by three mechanisms: constitutive secretion, regulated secretion and protease cell surface activity. Of these it is regulated secretion that responds to external stimuli and is amenable to therapeutic intervention in COPD and asthma. Regulated secretion involves release from intracellular granules by docking and fusion of the granules with the cell exterior to release their contents onto the airway surface. Fusion of the granules can either be with the plasma membrane of the epithelial cell or with the membrane of other granules leading to release via multigranular complexes fused at the cell surface. Regulated secretion of mucins is controlled by humoral factors and by neural mechanisms. The neural mechanisms in humans involve a minor contribution from the adrenergic, sympathetic pathway and a major cholinergic, parasympathetic component. Another important neural pathway regulating mucin secretion, particularly the hypersecretion of pathological conditions, is that of the Non-Adrenergic Non-Cholinergic (NANC) pathway. The NANC component involves both an orthodromic pathway involving neuropeptide and nonpeptide transmitters, and a local sensory efferent pathway involving antidromic fibres from sensory C fibres. [0004]
  • COPD is a common respiratory condition, being the fourth most common cause of death in middle age in the Western world. COPD comprises two related diseases, which usually occur together, emphysema and chronic bronchitis. The pathological basis of chronic bronchitis is mucus hypersecretion. The excessive, chronic bronchial secretion results in expectoration, and can last from a few days to many years. The mucus hypersecretion of COPD results in small airway obstruction producing reduced maximal respiratory flow and slow forced lung emptying. There is minimal reversal of the impaired airway function of COPD by bronchodilators and currently no effective therapy for the mucus hypersecretion. [0005]
  • Mucus hypersecretion is also a significant contributing factor to the pathophysiology of asthma. It is a key component in status asthmaticus, and contributes to the chronic symptoms and morbidity of asthma. The mucus hypersecretion component of asthma is not well controlled by current therapies, particularly in severe and chronic cases. [0006]
  • It would accordingly be desirable to treat, reduce or prevent the mucus hypersecretion that causes or leads to these disease conditions. [0007]
  • SUMMARY OF THE INVENTION
  • Accordingly, the invention provides a method of treating mucus hypersecretion comprising inhibiting mucus secretion by mucus secreting cells and/or inhibiting neurotransmitter release from neuronal cells that control or direct mucus secretion. The invention further provides, in a second aspect, a compound, for use in the treatment of mucus hypersecretion, which inhibits mucus secretion by (i) inhibiting mucus secretion by mucus secreting cells, or (ii) inhibiting neurotransmitter release from neuronal cells controlling or directing mucus secretion. [0008]
  • An advantage of the invention is that an agent for effective treatment of mucus hypersecretion and associated disease states is now provided and used, offering a relief to sufferers where hitherto there was no such agent available. [0009]
  • The present invention thus represents a new different approach to treatment of mucus hypersecretion by inhibiting secretory processes, namely one or other or both of the mucus secretion by mucus secretory cells and the secretion of neurotransmitters regulating mucus secretion. Agents of the present invention reduce mucus secretion and/or prevent the hypersecretion of COPD and asthma, and any other disease in which mucus hypersecretion is a causative element. [0010]
  • DETAILED DESCRIPTION OF THE INVENTION
  • A compound of the invention typically inhibits exocytosis in mucus secreting cells or neurones that control or direct mucus secretion. This compound is administered to a patient suffering from mucus hypersecretion and inhibition of exocytosis in the cells specified results in reduction of secretion of mucus. Specific disease states caused by or exacerbated by hypersecretion are localised to the airways, and hence an embodiment of the invention comprises topical administration to the airways or to a selected region or to a selected portion of the airways of a compound that inhibits exocytosis in mucus secreting cells or in neurones that control or direct mucus secretion. [0011]
  • A compound of embodiments of the invention is a polypeptide that consists of or comprises an inhibiting domain which inhibits exocytosis in the mucus secreting cell or inhibits exocytosis in a neuronal cell, thereby directly inhibiting exocytosis of mucus or one or more mucus components or indirectly inhibiting mucus secretion by inhibiting exocytosis of neurotransmitter which would in turn lead to or otherwise stimulate mucus secretion. The inhibiting domain can suitably comprise a light chain of a clostridial neurotoxin, or a fragment or variant thereof which inhibits exocytosis. [0012]
  • The compound preferably further comprises a translocating domain that translocates the inhibiting domain into the cell. This domain may comprise a H[0013] N region of a botulinum polypeptide, or a fragment or variant thereof that translocates the inhibiting domain into the cell.
  • The compound preferably comprises a targeting domain which binds to (i) a mucus secreting cell, or (ii) a neuronal cell controlling or directing mucus secretion. The compound is thus rendered specific for these cell types. It is also optional for the compound to be relatively non-specific but for inhibition of mucus secretion to be achieved via targeting of the compound through choice of route of administration—the compound is hence preferably administered to mucus secreting epithelial cells in the airways, specifically in the lungs. Whilst a non-specific compound of the invention may affect exocytosis in many cells of a wide range of types, generally only those cells that are stimulated will be affected and these stimulated cells will in typical disease states be those that are secreting mucus and contributing to disease. [0014]
  • When present, suitable targeting domains include, but are not restricted to, a domain selected from Substance P, VIP, beta[0015] 2 adrenoreceptor agonists, gastrin releasing peptide and calcitonin gene related peptide. The precise cells targeted in preferred embodiments of the invention are selected from (a) cells that secrete mucins, such as epithelial goblet cells and submucosal gland mucus secreting cells, (b) cells that secrete aqueous components of mucus, such as Clara cells and serous cells, and (c) cells that control or direct mucus secretion, such as “sensory-efferent” C-fibres, or NANC neural system fibres. The compound may be administered as a substantially pure preparation all targeted to the same cell type, or may be a mixture of compounds targeted respectively to different cells.
  • The compound of specific embodiments of the invention comprises first, second and third domains. The first domain is adapted to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis. This domain prevents exocytosis once delivered to a targeted cell. The second domain translocates the compound into the cell. This domain delivers the first domain into the cell. The third domain binds to the target cell, ie binds to (i) a mucus secreting cell, or (ii) a neuronal cell controlling or directing mucus secretion, and may be referred to as a targeting moiety (“TM”). The compound may be derived from a toxin and it is preferred that such a compound is free of clostridial neurotoxin and free of any clostridial neurotoxin precursor that can be converted into toxin. Botulinum and tetanus toxin are suitable sources of domains for the compounds of the invention. [0016]
  • In use, the agent of specific embodiments of the invention has a number of discrete functions. It binds to a surface structure (the Binding Site {BS}) which is characteristic of, and has a degree of specificity for, the relevant secretory cells and or neurones in the airways responsible for secretion of mucus and or regulation of said secretion. It enters the cell to which it binds by a process of endocytosis. Only certain cell surface BSs can undergo endocytosis, and preferably the BS to which the agent binds is one of these. The agent enters the cytosol, and modifies components of the exocytotic machinery present in the relevant secretory cells and or neurones in the airways responsible for secretion of mucus and or regulation of said secretion. [0017]
  • Surprisingly, agents of the present invention for treatment of mucus hypersecretion can be produced by modifying a clostridial neurotoxin or fragment thereof. The clostridial neurotoxins share a common architecture of a catalytic L-chain (LC, ca 50 kDa) disulphide linked to a receptor binding and translocating H-chain (HC, ca 100 kDa). The HC polypeptide is considered to comprise all or part of two distinct functional domains. The carboxy-terminal half of the HC (ca 50 kDa), termed the H[0018] C domain, is involved in the high affinity, neurospecific binding of the neurotoxin to cell surface receptors on the target neuron, whilst the amino-terminal half, termed the HN domain (ca 50 kDa), is considered to mediate the translocation of at least some portion of the neurotoxin across cellular membranes such that the functional activity of the LC is expressed within the target cell. The HN domain also has the property, under conditions of low pH, of forming ion-permeable channels in lipid membranes, this may in some manner relate to its translocation function.
  • For botulinum neurotoxin type A (BoNT/A) these domains are considered to reside within amino acid residues 872-1296 for the H[0019] C, amino acid residues 449-871 for the HN and residues 1-448 for the LC. Digestion with trypsin effectively degrades the HCcdomain of the BoNT/A to generate a non-toxic fragment designated L HN, which is no longer able to bind to and enter neurons. The LHN fragment so produced also has the property of enhanced solubility compared to both the parent holotoxin and the isolated LC.
  • It is therefore possible to provide functional definitions of the domains within the neurotoxin molecule, as follows: [0020]
  • (A) clostridial neurotoxin light chain: A metalloprotease exhibiting high substrate specificity for vesicle and/or plasma membrane associated proteins involved in the exocytotic process. In particular, it cleaves one or more of SNAP-25, VAMP (synaptobrevin/cellubrevin) and syntaxin. [0021]
  • (B) clostridial neurotoxin heavy chain HN domain: A portion of the heavy chain which enables translocation of that portion of the neurotoxin molecule such that a functional expression of light chain activity occurs within a target cell. [0022]
  • The domain responsible for translocation of the endopeptidase activity, following binding of neurotoxin to its specific cell surface receptor via the binding domain, into the target cell. [0023]
  • The domain responsible for formation of ion-permeable pores in lipid membranes under conditions of low pH. [0024]
  • The domain responsible for increasing the solubility of the entire polypeptide compared to the solubility of light chain alone. [0025]
  • (C) clostridial neurotoxin heavy chain HC domain. [0026]
  • A portion of the heavy chain which is responsible for binding of the native holotoxin to cell surface receptor(s) involved in the intoxicating action of clostridial toxin prior to internalisation of the toxin into the cell. [0027]
  • The identity of the cellular recognition markers for these toxins is currently not understood and no specific receptor species have yet been identified although Kozaki et al. have reported that synaptotagmin may be the receptor for botulinum neurotoxin type B. It is probable that each of the neurotoxins has a different receptor. [0028]
  • By covalently linking a clostridial neurotoxin, or a hybrid of two clostridial neurotoxins, in which the H[0029] C region of the H-chain has been removed or modified, to a new molecule or moiety, the Targeting Moiety (TM), that binds to a BS on the surface of the relevant secretory cells and or neurones in the airways responsible for secretion of mucus and or regulation of said secretion, a novel agent capable of inhibiting mucus secretion is produced. A further surprising aspect of the present invention is that if the L-chain of a clostridial neurotoxin, or a fragment of the L-chain containing the endopeptidase activity, is covalently linked to TM which can also effect internalisation of the L-chain, or a fragment of the L-chain containing the endopeptidase activity, into the cytoplasm of the relevant secretory cells and or neurones in the airways responsible for secretion of mucus and or regulation of said secretion, this also produces a novel agent capable of inhibiting mucus secretion.
  • Accordingly, the invention may thus provide a compound containing a first domain equivalent to a clostridial toxin light chain and a second domain providing the functional aspects of the H[0030] N of a clostridial toxin heavy chain, whilst lacking the functional aspects of a clostridial toxin HC domain, and a third domain which binds to the target mucus secreting or mucus secretion controlling cell.
  • For the purposes of the invention, the functional property or properties of the H[0031] N of a clostridial toxin heavy chain that are to be exhibited by the second domain of the polypeptide of the invention is translocation of the first domain into a target cell once the compound is proximal to the target cell. References hereafter to a HN domain or to the functions of a HN domain are references to this property or properties. The second domain is not required to exhibit other properties of the HN domain of a clostridial toxin heavy chain. A second domain of the invention can thus be relatively insoluble but retain the translocation function of a native toxin—this is of use if solubility is not essential to its administration or if necessary solubility is imparted to a composition made up of that domain and one or more other components by one or more of said other components.
  • The translocating domain may be obtained from a microbial protein source, in particular from a bacterial or viral protein source. It is well documented that certain domains of bacterial toxin molecules are capable of forming such pores. It is also known that certain translocation domains of virally expressed membrane fusion proteins are capable of forming such pores. Such domains may be employed in the present invention. [0032]
  • Hence, in one embodiment, the translocating domain is a translocating domain of an enzyme, such as a bacterial or viral toxin. One such molecule is the heavy chain of a clostridial neurotoxin, for example botulinum neurotoxin type A. Other sources of bacterial toxin translocating domains include diphtheria toxin and domain II of pseudomonas exotoxin. [0033]
  • Other sources of translocating domains include certain translocating domains of virally expressed membrane fusion proteins. For example, Wagner et al. (1992) and Murata et al. (1992) describe the translocation (i.e. membrane fusion and vesiculation) function of a number of fusogenic and amphiphilic peptides derived from the N-terminal region of influenza virus haemagglutinin. Other virally expressed membrane fusion proteins known to have the desired translocating activity are a translocating domain of a fusogenic peptide of Semliki Forest Virus (SFV), a translocating domain of vesicular stomatitis virus (VSV) glycoprotein G, a translocating domain of SER virus F protein and a translocating domain of Foamy virus envelope glycoprotein. Virally encoded “spike proteins” have particular application in the context of the present invention, for example, the E1 protein of SFV and the G protein of the G protein of VSV. [0034]
  • Preferably it has been found to use only those portions of the protein molecule capable of pore-formation within the endosomal membrane. [0035]
  • Methodology to enable assessment of membrane fusion and thus identification of translocation domains suitable for use in the present invention are provided by Methods in Enzymology Vol 220 and 221, Membrane Fusion Techniques, Parts A and B, Academic Press 1993. [0036]
  • Examples of preferred translocating domains for use in the present invention are listed in the table below. The below-listed citations are all herein incorporated by reference. [0037]
    Translocation Amino acid
    domain source residues References
    Diphtheria toxin 194-380 Silverman et al., 1994,
    J. Biol. Chem. 269,
    22524-22532
    London E., 1992,
    Biochem. Biophys.
    Acta., 1113, 25-51
    Domain II of 405-613 Prior et al., 1992,
    pseudomonas exotoxin Biochemistry 31, 3555-
    3559
    Kihara & Pastan, 1994,
    Bioconj Chem. 5, 532-
    538
    Influenza virus GLFGAIAGFIENGW Plank et al., 1994, J.
    haemagglutinin EGMIDGWYG (SEQ Biol. Chem. 269,
    ID NO: 1), and 12918-12924
    variants thereof Wagner et al., 1992,
    PNAS, 89, 7934-7938
    Murata et al., 1992,
    Biochemistry 31, 1986-
    1992
    Semliki Forest virus Translocation domain Kielian et al., 1996, J
    fusogenic protein Cell Biol. 134 (4),
    863-872
    Vesicular Stomatitis 118-139 Yao et al., 2003,
    virus glycoprotein G Virology 310 (2), 319-
    332
    SER virus F protein Translocation domain Seth et al., 2003, J
    Virol 77 (11) 6520-
    6527
    Foamy virus envelope Translocation domain Picard-Maureau et al.,
    glyoprotein 2003, J Virol. 77 (8),
    4722-4730
  • Use of the translocating domains listed in the above table includes use of sequence variants thereof. A variant may comprise one or more conservative nucleic acid substitutions and/or nucleic acid deletions or insertions, with the proviso that the variant possesses the requisite translocating function. A variant may also comprise one or more amino acid substitutions and/or amino acid deletions or insertions, so long as the variant possesses the requisite translocating function. [0038]
  • The only functional requirement of the translocating domain is that it is capable of forming appropriate pores in the endosomal membrane. A number of routine methods are available for confirming that a particular translocating domain has the requisite translocating activity, and thus to determine the presence of a translocating domain. Shone et al. (1987), and Blaustein et al. (1987) provide details of two very simple assays to confirm that any particular bacterial translocating domain has the requisite translocating activity. Shone (1987) describes a simple in vitro assay employing liposomes, which are challenged with a test molecule. The presence of a molecule having the requisite translocating function is confirmed by release from the liposomes of K[0039] + and/or labelled NAD. Blaustein (1987) describes a simple in vitro assay employing planar phospholipid bilayer membranes, which are challenged with a test molecule. The presence of a molecule having the requisite translocation function is confirmed by an increase in conductance across the phospholipid membrane.
  • The polypeptide of the invention may be obtained by expression of a recombinant nucleic acid, preferably a DNA, and is a single polypeptide, that is to say not cleaved into separate light and heavy chain domains. The polypeptide is thus available in convenient and large quantities using recombinant techniques. [0040]
  • The first domain optionally comprises a fragment or variant of a clostridial toxin light chain. The fragment is optionally an N-terminal, or C-terminal fragment of the light chain, or is an internal fragment, so long as it substantially retains the ability to cleave the vesicle or plasma-membrane associated protein essential to exocytosis. Domains necessary for the activity of the light chain of clostridial toxins are described in J. Biol. Chem., Vol.267, No. 21, July 1992, pages 14721-14729. The variant has a different peptide sequence from the light chain or from the fragment, though it too is capable of cleaving the vesicle or plasma-membrane associated protein. It is conveniently obtained by insertion, deletion and/or substitution of a light chain or fragment thereof. In embodiments of the invention described below a variant sequence comprises (i) an N-terminal extension to a clostridial toxin light chain or fragment (ii) a clostridial toxin light chain or fragment modified by alteration of at least one amino acid (iii) a C-terminal extension to a clostridial toxin light chain or fragment, or (iv) combinations of 2 or more of (i)-(iii). [0041]
  • In an embodiment of the invention described in an example below, the toxin light chain and the portion of the toxin heavy chain are of botulinum toxin type A. In a further embodiment of the invention described in an example below, the toxin light chain and the portion of the toxin heavy chain are of botulinum toxin type B. The polypeptide optionally comprises a light chain or fragment or variant of one toxin type and a heavy chain or fragment or variant of another toxin type. [0042]
  • In a polypeptide according to the invention said second domain preferably comprises a clostridial toxin heavy chain H[0043] N portion or a fragment or variant of a clostridial toxin heavy chain HN portion. The fragment is optionally an N-terminal or C-terminal or internal fragment, so long as it retains the function of the HN domain. Teachings of regions within the HN responsible for its function are provided for example in Biochemistry 1995,34, pages 15175-15181 and Eur. J. Biochem, 1989,185, pages 197-203. The variant has a different sequence from the HN domain or fragment, though it too retains the function of the HN domain. It is conveniently obtained by insertion, deletion and/or substitution of a HN domain or fragment thereof. In embodiments of the invention, described below, it comprises (i) an N-terminal extension to a HN domain or fragment, (ii) a C-terminal extension to a HN domain or fragment, (iii) a modification to a HN domain or fragment by alteration of at least one amino acid, or (iv) combinations of 2 or more of (i)-(iii). The clostridial toxin is preferably botulinum toxin or tetanus toxin.
  • These polypeptides of the invention thus typically contain two or more polypeptide first and second domain, linked by di-sulphide bridges into composite molecules, and further linked to a third domain. [0044]
  • The TM provides specificity for the BS on the relevant neuronal and or secretory cells responsible for secretion of mucus in the airways. The TM component of the agent can comprise one of many cell binding molecules, including, but not limited to, antibodies, monoclonal antibodies, antibody fragments (Fab, F(ab)′[0045] 2, Fv, ScFv, etc.), lectins, hormones, cytokines, growth factors or peptides.
  • It is known in the art that the H[0046] C portion of the neurotoxin molecule can be removed from the other portion of the H-chain, known as HN, such that the HN fragment remains disulphide linked to the L-chain of the neurotoxin providing a fragment known as LHN. Thus, in one embodiment of the present invention the LHN fragment of a clostridial neurotoxin is covalently linked, using linkages which may include one or more spacer regions, to a TM.
  • The H[0047] C domain of a clostridial neurotoxin may be mutated or modified, eg by chemical modification, to reduce or preferably incapacitate its ability to bind the neurotoxin to receptors at the neuromuscular junction. This modified clostridial neurotoxin is then covalently linked, using linkages which may include one or more spacer regions, to a TM.
  • The heavy chain of a clostridial neurotoxin, in which the H[0048] C domain is mutated or modified, eg by chemical modification, to reduce or preferably incapacitate its ability to bind the neurotoxin to receptors at the neuromuscular junction, may be combined with the L-chain of a different clostridial neurotoxin. This hybrid, modified clostridial neurotoxin is then covalently linked, using linkages which may include one or more spacer regions, to a TM.
  • In another embodiment of the invention, the H[0049] N domain of a clostridial neurotoxin is combined with the L-chain of a different clostridial neurotoxin. This hybrid LHN is then covalently linked, using linkages which may include one or more spacer regions, to a TM. In a further embodiment of the invention, the light chain of a clostridial neurotoxin, or a fragment of the light chain containing the endopeptidase activity, is covalently linked, using linkages which may include one or more spacer regions, to a TM which can also effect the internalisation of the L-chain, or a fragment of the L-chain containing the endopeptidase activity, into the cytoplasm of the relevant secretory and/or neuronal cells in the airways responsible for secretion of mucus and or regulation of said secretion.
  • The agent is optionally expressed recombinantly as a fusion protein which includes an appropriate TM in addition to any desired spacer regions. The recombinantly expressed agent may be derived wholly from the gene encoding one serotype of neurotoxin or may be a chimaera derived from genes encoding one or more serotypes. In another embodiment of the invention the required LH[0050] N, which may be a hybrid of an L and HN from different clostridial types, is expressed recombinantly as a fusion protein with the TM, and may include one or more spacer regions.
  • The light chain of a clostridial neurotoxin, or a fragment of the light chain containing the endopeptidase activity, may be expressed recombinantly as a fusion protein with a TM which can also effect the internalisation of the L-chain, or a fragment of the L-chain containing the endopeptidase activity, into the cytoplasm of the relevant secretory and or neuronal cells in the airways responsible for secretion of mucus and or regulation of said secretion. The expressed fusion protein may also include one or more spacer regions. [0051]
  • A neurotoxin fragment as described in the present invention can be prepared by methods well known in the protein art, including, but not limited to, proteolytic cleavage or by genetic engineering strategies. Said fragment is preferably a non-toxic fragment. The conjugation may be chemical in nature using chemical or covalent linkers. Conjugates according to the present invention may be prepared by conventional methods known in the art. [0052]
  • In a third aspect, the invention provides a composition for use in treating mucus hypersecretion, comprising: [0053]
  • a compound according to any of the second aspect of the invention; and [0054]
  • at least one of a pharmaceutically acceptable excipient, adjuvant and/or propellant, [0055]
  • wherein the composition is for administration to the airways of a patient. [0056]
  • Aerosol administration is a preferred route of administration, though the present invention encompasses also any administration that delivers the compound to epithelia in the airways. Nasal administration is optional though buccal is preferred. The compound may thus be formulated for oral administration via aerosol or nebuliser or as a dry powder for inhalation using conventional excipients, adjuvants and/or propellants. The invention therefore further provides a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable carrier. [0057]
  • In use the compound will generally be employed in a pharmaceutical composition in association with a human pharmaceutical carrier, diluent and/or excipient, although the exact form of the composition will depend on the mode of administration. The compound may, for example, be employed in the form of an aerosol or nebulisable solution. [0058]
  • In a specific embodiment of the invention, described in further detail below, a polypeptide according to the invention comprises Substance P, and an L chain and a heavy chain H[0059] N region of botulinum toxin A. In use, this may be administered to a patient by aerosol. A solution of the polypeptide is prepared and converted into an aerosol using a nebuliser for inhalation into the lungs of nebulised particles of diameter 1-5 microns.
  • The dosage ranges for administration of the compounds of the present invention are those to produce the desired therapeutic effect. It will be appreciated that the dosage range required depends on the precise nature of the conjugate, the route of administration, the nature of the formulation, the age of the patient, the nature, extent or severity of the patient's condition, contraindications, if any, and the judgement of the attending physician. Wide variations in the required dosage, however, are to be expected depending on the precise nature of the conjugate. Variations in these dosage levels can be adjusted using standard empirical routines for optimisation, as is well understood in the art. [0060]
  • Fluid unit dosage forms are prepared utilising the compound and a pyrogen-free sterile vehicle. The compound, depending on the vehicle and concentration used, can be either dissolved or suspended in the vehicle. In preparing solutions the compound can be dissolved in the vehicle, the solution being made isotonic if necessary by addition of sodium chloride and sterilised by filtration through a sterile filter using aseptic techniques before filling into suitable sterile vials or ampoules and sealing. Alternatively, if solution stability is adequate, the solution in its sealed containers maybe sterilised by autoclaving. Advantageously additives such as buffering, solubilising, stabilising, preservative or bactericidal, suspending or emulsifying agents and/or local anaesthetic agents may be dissolved in the vehicle. [0061]
  • Dry powders which are dissolved or suspended in a suitable vehicle prior to use may be prepared by filling pre-sterilised drug substance and other ingredients into a sterile container using aseptic technique in a sterile area. Alternatively the drug and other ingredients may be dissolved into suitable containers using aseptic technique in a sterile area. The product is then freeze dried and the containers are sealed aseptically. [0062]
  • Compositions suitable for administration via the respiratory tract include aerosols, nebulisable solutions or microfine powders for insufflation. In the latter case, particle size of less than 50 microns, especially less than 10 microns, is preferred. Such compositions may be made up in a conventional manner and employed in conjunction with conventional administration devices. [0063]
  • In further aspects of the invention, there is provided use of a compound that inhibits exocytosis in mucus secreting cells or neurones that control or direct mucus secretion in manufacture of a medicament for treating mucus hypersecretion, asthma or COPD. [0064]
  • The invention yet further provides a method of manufacture of a pharmaceutical composition, comprising:—[0065]
  • obtaining a clostridial neurotoxin and modifying it so as to remove or disable its H[0066] C portion; or
  • obtaining a clostridial neurotoxin the H[0067] C portion of which has been removed or disabled;
  • linking the toxin with a targeting moiety that binds to (i) a mucus secreting cell, or (ii) a neuronal cell that controls or directs mucus secretion. [0068]
  • The invention still further provides a method of manufacture of a pharmaceutical composition, comprising obtaining a first component having the domains: [0069]
  • an inhibiting domain which inhibits exocytosis in a mucus secreting cell or neuronal cell that controls or directs mucus secretion; [0070]
  • a translocating domain which translocates the inhibiting domain into the cell; and [0071]
  • linking the first component to a second component that binds to (i) a mucus secreting cell, or (ii) a neuronal cell that controls or directs mucus secretion. [0072]
  • The first and second components are preferably formulated in an orally administrable composition in combination with one or more or an excipient, an adjuvant and a propellant.[0073]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • Specific embodiments of the invention are now illustrated in the following examples with reference to the accompanying drawings in which:—[0074]
  • FIG. 1 illustrates the preparation of the substance P-LH[0075] N/A conjugate of Example 1;
  • FIG. 2 shows Western blot detection of conjugated substance P-LH[0076] N/A;
  • FIG. 3 shows SDS-PAGE analysis of a WGA-LH[0077] N/A purification scheme;
  • FIGS. [0078] 4-6 show inhibition of neurotransmitter release from cultured neuronal cells; and
  • FIG. 7 shows WGA-LH[0079] N/A inhibits release from, but does not have specificity for, eDRG neurons.
  • EXAMPLES Example 1 Method for the Preparation of Substance P-LHN/A Conjugates
  • The lyophilised peptide was rehydrated in 0.1% trifluoroacetic acid (TFA) to a final concentration of 10 mM. Aliquots of this solution were stored at −20 degrees C. until use. The LH[0080] N/A was desalted into PBSE (PBS containing 1 mM EDTA). The resulting solution (3-5 mg/ml) was reacted with a three- or four-fold molar excess of SPDP by addition of a 10 mM stock solution of SPDP in DMSO. After 3 hours at room temperature the reaction was terminated by desalting over a PD-10 column into PBSE.
  • A portion of the derivatised LH[0081] N/A was removed from the solution and reduced with DTT (5 mM, 30 min). This sample was analysed spectrophotometrically at 280 nm and 343 nm to determine the degree of derivatisation. The degree of derivatisation achieved was typically 2 mol/mol.
  • The bulk of the derivatised LH[0082] N/A and the substance P peptide were mixed in proportions such that the peptide was in four-fold molar excess. The conjugation reaction was allowed to proceed for >16 hours at 4° C.
  • The product mixture was centrifuged to clear any precipitate that had developed. The supernatant was applied to a PD-10 column equilibrated in PBS and protein fractions were eluted by addition of PBS. Peptide and reaction by-products eluted after the main peak of protein and were discarded. [0083]
  • The conjugate mixture was concentrated to >1 mg/ml by centrifugation through concentrators (with 10000 molecular weight exclusion limit). The concentrated conjugate mixture was analysed by SDS-PAGE and Western blotting (probed with anti-substance P antibody) to confirm linkage of substance P peptide to LH[0084] N/A.
  • The method described is for linkage of substance P peptide covalently to LH[0085] N/A via a SPDP linker. A sulphydryl residue is incorporated into the C-terminus of the substance P residue, in this case by the addition of a Cys residue. Alternative linkers are available, including linkers utilising similar chemistry of derivatisation but generating non-reducible covalent bonds between the linked species.
  • The Substance P peptide sequence used in this particular example is RPKPQQFFGLMC (SEQ ID NO:2), though alternative sequences are also suitable, e.g. CRPKPQQFFGLM (SEQ ID NO:3), i.e. substance P with an N-terminal Cys. [0086]
  • The method described does not make use of any tagging system (e.g. poly His) to purify the conjugate from free LH[0087] N/A. This has been demonstrated to be a successful method for the preparation of opioid peptide LHN/A such the receptor binding function of the peptide was not compromised. A similar approach can be applied to the synthesis of subP-LHN/A.
  • FIG. 1 illustrates the preparation of the substance P-LH[0088] N/A conjugate of Example 1. In the results shown in FIG. 1, LHN/A and substance P-LHN/A samples at the concentrations indicated were applied to nitrocellulose and probed with rabbit anti-substance P antibody (upper two rows). The emergence of cross-reaction with the conjugate (second row), rather than the LHN/A (first row), is indicative of substance P conjugated to LHN/A. The lower control row illustrates the presence of LHN/A.
  • FIG. 2 shows Western blot detection of conjugated substance P-LH[0089] N/A. Samples of substance P-LHN/A (lane 3) and LHN/A (lane 2) were electrophoresed alongside molecular weight markers (lane 1). Detection of substance P by rat anti-substance P antisera indicated protein of approx. 100 kDa molecular weight in the conjugate lane, but no such band in the LHN/A only lane. Thus the conjugated LHN/A does contain substance P.
  • Example 2 Method for the Preparation of a Broad Specificity Agent
  • Conjugation and purification of WGA-LH[0090] N/A. WGA (10 mg/ml in phosphate-buffered saline (PBS)) was reacted with an equal concentration of SPDP (10 mM in dimethyl sulphoxide (DMSO)) for one hour at ambient temperature. Reaction by-products were removed by desalting into PBS prior to reduction of the cross-linker with dithiothreitol. The thiopyridone and DTT were then removed by desalting into PBS to result in derivatised WGA (dWGA) with 1 mole —SH incorporated per mole of WGA.
  • LH[0091] N/A at a concentration of 3-5 mg/ml in PBSE (PBS containing 1 mM EDTA) was reacted with a three or four-fold molar excess of SPDP (10 mM in DMSO). After 3 h at ambient temperature the reaction was terminated by desalting over a PD-10 column into PBSE.
  • The derivatised WGA (dWGA) and the derivatised LHN/A (dLHN/A) were mixed in a 3:1 molar ratio. After 16 h at 4° C. the mixture was centrifuged to clear any precipitate that had developed. The supernatant was concentrated by ultrafiltration before application to a Superose™ 12 column on an FPLC® chromatography system (Pharmacia). The column was eluted with PBS and the fractions containing high molecular weight conjugate material (separated from free dWGA) were pooled and applied to PBS-washed N-acetylglucosamine-agarose (GlcNAc-agarose). WGA-LHN/A conjugate bound to the GlcNAc-agarose and was eluted from the column by the addition of 0.3M N-acetylglucosamine in PBS. The elution profile was followed at 280 nm and fractions containing conjugate were pooled, dialysed against PBS, and stored at 4° C. until use. [0092]
  • FIG. 3 shows SDS-PAGE analysis of WGA-LH[0093] N/A purification scheme. Protein fractions were subjected to 4-20% polyacrylamide SDS-PAGE prior to staining with Coomassie blue. Lanes 6-8 were run in the presence of 0.1M DTT. Lanes 1 (&7) and 2 (& 8) represent derivatised WGA and derivatised LHN/A respectively. Lanes 3-5 represent conjugation mixture, post-Superose-12 chromatography and post GlcNAc-affinity chromatography respectively. Lanes 6 represents a sample of reduced final material. Approximate molecular masses (kDa) are indicated on the Figure.
  • Example 3 Preparation and Maintenance of Neuronal Cultures and Inhibition of Neurotransmitter Release
  • PC12 cells were seeded at a density of 4×10[0094] 5 cells/well onto 24 well (matrigel coated) plates (NUNC™) from stocks grown in suspension. The cells were cultured for 1 week prior to use in RPMI, 10% horse serum, 5% foetal bovine serum, 1% L-glutamine. SH-SY5Y cells were seeded at a density of 5×105 cells/well onto 24 well plates (FALCON™). The cells were cultured in HAM-F12:MEM (1:1 v/v), 15% foetal bovine serum, 1% MEM non-essential amino acids, 2 mM L-glutamine for 1 week prior to use. Embryonic spinal cord (eSC) neurons were prepared from spinal cords dissected from 14-15 day old foetal Sprague Dawley rats and were used after 21 days in culture using a modification of previously described method.
  • Inhibition of transmitter release. PC12 cells or SH-SY5Y cells were washed with a balanced salt solution (BSS: 137 mM NaCl, 5 mM KCl, 2 mM CaCl[0095] 2, 4.2 mMNaHCO3, 1.2 mM MgCl2, 0.44 mM KH2PO4, 5 mM glucose, 20 mM HEPES, pH 7.4) and loaded for 1 hour with [3H]-noradrenaline (2 μCi/ml, 0.5 ml/well) in BSS containing 0.2 mM ascorbic acid and 0.2 mM pargyline. Cells were washed 4 times (at 15 minutes intervals for 1 hour) then basal release determined by a 5 minute incubation with BSS (5 mM K+). Cells were then depolarised with 100 mM K+ (BSS with Na+ reduced accordingly) for 5 minutes to determine stimulated release. Superfusate (0.5 ml) was removed to tubes on ice and briefly centrifuged to pellet any detached cells. Adherent cells were solubilised in 2M acetic acid/0.1% trifluoroacetic acid (250 μl/well). The quantity of released and non-released radiolabel was determined by liquid scintillation counting of cleared superfusates and cell lysates respectively. Total uptake was calculated by addition of released and retained radioactivity and the percentage release calculated ((released counts/total uptake counts)×100).
  • eSC neurons were loaded with [[0096] 3H]-glycine for 30 minutes prior to determination of basal and potassium-stimulated release of transmitter. A sample of 0.2M NaOH-lysed cells was used to determine total counts, from which % release could be calculated.
  • FIGS. [0097] 4-6 show inhibition of neurotransmitter release from cultured neuronal cells. PC12 (FIG. 4), SH-SY5Y cells (FIG. 5) and eSC neurons (FIG. 6) exposed for three days to a range of concentrations of WGA-LHN/A (filled symbols) and LHN/A (open symbols) were assessed for stimulated [3H]-noradrenaline release (SH-SY5Y and PC12 cells) or [3H]-glycine release (eSC) capability. Results are expressed as percentage inhibition compared to untreated controls. Each concentration was assessed in triplicate. For each cell type the dose response curve is representative of at least three experiments. Each point shown is the mean of at least three determinations ±SE of the mean.
  • FIG. 7 shows dose-response curves of WGA-LH[0098] N/A inhibition of eDRG substance P and eSC [3H]-glycine release. Cells were exposed to conjugate for three days. Representative curves are shown. Mean IC50 eDRG: 0.32±0.05 μg/ml (n=4), eSC: 0.06±0.01 μg/ml (n=3).
  • Example 4 Method for the Preparation of LC/B-Epidermal Growth Factor with a Translocation Domain from Diphtheria Toxin by Recombinant Expression
  • Using standard DNA manipulation procedures, the DNA encoding LC/B, diphtheria toxin amino acids 194-380, and epidermal growth factor are assembled in frame and inserted into an appropriate expression vector. Inserted between the LC/B DNA and the diphtheria toxin translocation domain is DNA encoding a short spacer sequence with a specific cleavable peptide bond (↓), bounded by a pair of cysteine amino acids. Examples of specific enzymes that may be used to activate the fusion protein include factor Xa (IEGRι) (SEQ ID NO:4), enterokinase (DDDDK↓) (SEQ ID NO:5), TEV protease (EXXYXQS↓G) (SEQ ID NO:6), precission (LEVLFQ↓GP) (SEQ ID NO:7), Thrombin (LVPR↓GS) (SEQ ID NO:8) and genenase (HY or YH). Expression of a single polypeptide of the form LC/B-DT[0099] 194-380-EGF is achieved in E. coli using standard techniques. The expressed fusion protein is isolated from E. coli by standard purification techniques and cleaved by the specific activation enzyme prior to assessment in an in vitro cell model.
  • Example 5 Method for the Preparation of LC/C-Epidermal Growth Factor with a Translocation Domain from Pseudomonas Exotoxin by Recombinant Expression
  • Using standard DNA manipulation procedures, the DNA encoding LC/C, pseudomonas exotoxin amino acids 405-613, and epidermal growth factor are assembled in frame and inserted into an appropriate expression vector. Inserted between the LC/C DNA and the pseudomonas exotoxin translocation domain is DNA encoding a short spacer sequence with a specific cleavable peptide bond, bounded by a pair of cysteine amino acids. Examples of specific enzymes that may be used to activate the fusion protein include factor Xa (IEGR↓), (SEQ ID NO:4), enterokinase (DDDDK↓) (SEQ ID NO:5), TEV protease (EXXYXQS↓G) (SEQ ID NO:6), precission (LEVLFQ↓GP) (SEQ ID NO:7), Thrombin (LVPR↓GS) (SEQ ID NO:8) and genenase (HY or YH). Expression of a single polypeptide of the form LC/C-PE[0100] 405-613-EGF is achieved in E. coli using standard techniques. The expressed fusion protein is isolated from E. coli by standard purification techniques and cleaved by the specific activation enzyme prior to assessment in an in vitro cell model.
  • Example 6 Method for the Preparation of LC/A-Epidermal Growth Factor with a Translocation Domain from Influenza Virus Haemagglutinin by Recombinant Expression
  • Using standard DNA manipulation procedures, the DNA encoding LC/A, GLFGAIAGFIENGWEGMIDGWYG (SEQ ID NO:1) from influenza virus haemagglutinin (HA), and epidermal growth factor are assembled in frame and inserted into an appropriate expression vector. Inserted between the LC/A DNA and the haemagglutinin sequence is DNA encoding a short spacer sequence with a specific cleavable peptide bond, bounded by a pair of cysteine amino acids. Examples of specific enzymes that may be used to activate the fusion protein include factor Xa (IEGR↓) (SEQ ID NO:4), enterokinase (DDDDK↓) (SEQ ID NO:5), TEV protease (EXXYXQS↓G) (SEQ ID NO:6), precission (LEVLFQ↓GP) (SEQ ID NO:7), Thrombin (LVPR↓GS) (SEQ ID NO:8) and genenase (HY or YH). Expression of a single polypeptide of the form LC/A-HAEGF is achieved in [0101] E. coli using standard techniques. The expressed fusion protein is isolated from E. coli by standard purification techniques and cleaved by the specific activation enzyme prior to assessment in an in vitro cell model.
  • The agent described in this invention can be used in vivo, either directly or as a pharmaceutically acceptable salt, for the treatment of conditions involving mucus hypersecretion, including COPD and asthma. [0102]
  • 1 8 1 23 PRT Influenza virus 1 Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Asn Gly Trp Glu Gly 1 5 10 15 Met Ile Asp Gly Trp Tyr Gly 20 2 12 PRT Unknown Substance P peptide sequence 2 Arg Pro Lys Pro Gln Gln Phe Phe Gly Leu Met Cys 1 5 10 3 12 PRT Unknown Substance P peptide sequence with N-terminal Cys 3 Cys Arg Pro Lys Pro Gln Gln Phe Phe Gly Leu Met 1 5 10 4 4 PRT Unknown Factor Xa 4 Ile Glu Gly Arg 1 5 5 PRT Unknown Enterokinase 5 Asp Asp Asp Asp Lys 1 5 6 8 PRT Unknown TEV protease 6 Glu Xaa Xaa Tyr Xaa Gln Ser Gly 1 5 7 8 PRT Unknown Precission 7 Leu Glu Val Leu Phe Gln Gly Pro 1 5 8 6 PRT Unknown Thrombin 8 Leu Val Pro Arg Gly Ser 1 5

Claims (54)

What is claimed is:
1. A method of treating hypersecretion of mucus, comprising administering, topically to the airways of a patient in need thereof, a therapeutically effective amount of a compound, said compound comprising:—
(a) a light chain (L-chain) or L-chain fragment of a clostridial neurotoxin, which L-chain or L-chain fragment includes the active proteolytic enzyme domain of the L-chain;
(b) a targeting domain that binds to a target cell selected from the group consisting of (i) a mucus secreting cell, and (ii) a neuronal cell controlling or directing mucus secretion; and
(c) a translocating domain that translocates the L-chain or L-chain fragment into the target cell;
with the proviso that said compound is not a botulinum toxin; and wherein, following administration to said patient, the compound binds to and delivers the L-chain or L-chain fragment into said target cell, thereby (i) inhibiting mucus secretion by mucus secreting cells, (ii) inhibiting neurotransmitter release from neuronal cells controlling or directing mucus secretion, or (iii) inhibiting mucus secretion by mucus secreting cells and inhibiting neurotransmitter release from neuronal cells controlling or directing mucus secretion.
2. A method according to claim 1, wherein said translocating domain is a translocating domain of a microbial protein.
3. A method according to claim 1, wherein said translocating domain is a translocating domain of a bacterial or viral protein.
4. A method according to claim 1, wherein said translocating domain is a translocating domain of a bacterial toxin, or a translocating domain of a virally expressed membrane fusion protein.
5. A method according to claim 1, wherein said translocating domain is selected from the group consisting of a translocating domain of diphtheria toxin, domain II of pseudomonas exotoxin A, a translocating domain of influenza virus haemagglutinin, a translocating domain of a fusogenic protein of Semliki Forest virus, a translocating domain of vesicular stomatitis virus glycoprotein G, a translocating domain of SER virus F protein and a translocating domain of Foamy virus envelope glycoprotein.
6. A method according to claim 1, wherein the targeting domain is a domain selected from the group consisting of Substance P, vasoactive intestinal polypeptide (VIP), beta2 adrenoreceptor agonists, gastrin releasing peptide, and calcitonin gene related peptide.
7. A method according to claim 1, wherein said targeting domain binds to a target cell selected from the group consisting of epithelial goblet cells, submucosal gland mucus-secreting cells, Clara cells, serous cells, sensory efferent C-fibres, and Non-adrenergic Non-Cholinergic neural system fibres.
8. A method of treating chronic obstructive pulmonary disease (COPD), comprising administering, topically to the airways of a patient in need thereof, a therapeutically effective amount of a compound, said compound comprising:—
(a) a light chain (L-chain) or L-chain fragment of a clostridial neurotoxin, which L-chain or L-chain fragment includes the active proteolytic enzyme domain of the L-chain;
(b) a targeting domain that binds to a target cell selected from the group consisting of (i) a mucus secreting cell, and (ii) a neuronal cell controlling or directing mucus secretion; and
(c) a translocating domain of that translocates the L-chain or L-chain fragment into the target cell;
with the proviso that said compound is not a botulinum toxin; and
wherein following administration to said patient the compound binds to and delivers the L-chain or L-chain fragment into said target cell, thereby (i) inhibiting mucus secretion by mucus secreting cells, (ii) inhibiting neurotransmitter release from neuronal cells controlling or directing mucus secretion, or (iii) inhibiting mucus secretion by mucus secreting cells and inhibiting neurotransmitter release from neuronal cells controlling or directing mucus secretion.
9. A method according to claim 8, wherein said translocating domain is a translocating domain of a microbial protein.
10. A method according to claim 8, wherein said translocating domain is a translocating domain of a bacterial or viral protein.
11. A method according to claim 8, wherein said translocating domain is a translocating domain of a bacterial toxin, or a translocating domain of a virally expressed membrane fusion protein.
12. A method according to claim 8, wherein said translocating domain is selected from the group consisting of a translocating domain of diphtheria toxin, domain II of pseudomonas exotoxin A, a translocating domain of influenza virus haemagglutinin, a translocating domain of a fusogenic protein of Semliki Forest virus, a translocating domain of vesicular stomatitis virus glycoprotein G, a translocating domain of SER virus F protein and a translocating domain of Foamy virus envelope glycoprotein.
13. A method according to claim 8, wherein the targeting domain is a domain selected from the group consisting of Substance P, VIP, beta2 adrenoreceptor agonists, gastrin releasing peptide, and calcitonin gene related peptide.
14. A method according to claim 8, wherein said targeting domain selectively binds to a target cell selected from the group consisting of epithelial goblet cells, submucosal gland mucus-secreting cells, Clara cells, and serous cells.
15. A method for treating asthma, comprising administering, topically to the airways of a patient in need thereof, a therapeutically effective amount of a compound, said compound comprising:—
(a) a light chain (L-chain) or L-chain fragment of a clostridial neurotoxin, which L-chain or L-chain fragment includes the active proteolytic enzyme domain of the L-chain;
(b) a targeting domain that binds to a target cell selected from the group consisting of (i) a mucus secreting cell, and (ii) a neuronal cell controlling or directing mucus secretion; and
(c) a translocating domain that translocates the L-chain or L-chain fragment into the target cell;
with the proviso that said compound is not a botulinum toxin; and wherein following administration to said patient the compound binds to and delivers the L-chain or L-chain fragment into said target cell, thereby (i) inhibiting mucus secretion by mucus secreting cells, (ii) inhibiting neurotransmitter release from neuronal cells controlling or directing mucus secretion, or (iii) inhibiting mucus secretion by mucus secreting cells and inhibiting neurotransmitter release from neuronal cells controlling or directing mucus secretion.
16. A method according to claim 15, wherein said translocating domain is a translocating domain of a microbial protein.
17. A method according to claim 15, wherein said translocating domain is a translocating domain of a bacterial or viral protein.
18. A method according to claim 15, wherein said translocating domain is a translocating domain of a bacterial toxin, or a translocating domain of a virally expressed membrane fusion protein.
19. A method according to claim 15, wherein said translocating domain is selected from the group consisting of a translocating domain of diphtheria toxin, domain II of pseudomonas exotoxin A, a translocating domain of influenza virus haemagglutinin, a translocating domain of a fusogenic protein of Semliki Forest virus, a translocating domain of vesicular stomatitis virus glycoprotein G, a translocating domain of SER virus F protein and a translocating domain of Foamy virus envelope glycoprotein.
20. A method according to claim 15, wherein the targeting domain is a domain selected from the group consisting of Substance P, VIP, beta2 adrenoreceptor agonists, gastrin releasing peptide, and calcitonin gene related peptide.
21. A method according to claim 15, wherein said targeting domain selectively binds to a target cell selected from the group consisting of epithelial goblet cells, submucosal gland mucus-secreting cells, Clara cells, and serous cells.
22. A compound which inhibits mucus secretion by mucus secreting cells, said compound comprising:—
(a) a light chain (L-chain) or L-chain fragment of a clostridial neurotoxin, which L-chain or L-chain fragment includes the active proteolytic enzyme domain of the L-chain;
(b) a targeting domain that selectively binds to a target cell that is a mucus secreting cell; and
(c) a translocating domain that translocates the L-chain or L-chain fragment into the target cell;
with the proviso that said compound is not a botulinum toxin.
23. A compound according to claim 22, wherein said translocating domain is a translocating domain of a microbial protein.
24. A compound according to claim 22, wherein said translocating domain is a translocating domain of a bacterial or viral protein.
25. A compound according to claim 22, wherein said translocating domain is a translocating domain of a bacterial toxin, or a translocating domain of a virally expressed membrane fusion protein.
26. A compound according to claim 22, wherein said translocating domain is selected from the group consisting of a translocating domain of diphtheria toxin, domain II of pseudomonas exotoxin A, a translocating domain of influenza virus haemagglutinin, a translocating domain of a fusogenic protein of Semliki Forest virus, a translocating domain of vesicular stomatitis virus glycoprotein G, a translocating domain of SER virus F protein and a translocating domain of Foamy virus envelope glycoprotein.
27. The compound according to claim 22, wherein the targeting domain is a domain selected from the group consisting of Substance P, VIP, beta2 adrenoreceptor agonists, gastrin releasing peptide, and calcitonin gene related peptide.
28. The compound according to claim 22, wherein said targeting domain selectively binds to a target cell selected from the group consisting of epithelial goblet cells, submucosal gland mucus-secreting cells, Clara cells, and serous cells.
29. A compound according to claim 22, wherein said targeting domain binds to (i) a mucus secreting cell, but not to (ii) a neuronal cell controlling or directing mucus secretion.
30. A compound according to claim 29, wherein the targeting domain is a domain selected from the group consisting of Substance P, VIP, beta2 adrenoreceptor agonists, gastrin releasing peptide and calcitonin gene related peptide.
31. A compound according to claim 29, wherein said targeting domain binds to a target cell selected from the group consisting of epithelial goblet cells, submucosal gland mucus-secreting cells, Clara cells, and serous cells.
32. A pharmaceutical composition for topical administration to airways of a patient suffering from mucus hypersecretion, comprising:—
(a) an amount of a compound, effective to inhibit mucus hypersecretion, wherein the compound comprises:—
(i) a light chain (L-chain) or L-chain fragment of a clostridial neurotoxin, which L-chain or L-chain fragment includes the active proteolytic enzyme domain of the L-chain;
(ii) a targeting domain that selectively binds to a target cell that is a mucus secreting cell; and
(iii) a translocating domain that translocates the L-chain or L-chain fragment into the target cell;
with the proviso that said compound is not a botulinum toxin; and
(b) a formulation component selected from the group consisting of an excipient, an adjuvant and a propellant;
wherein the composition is for nasal or oral administration of the compound to a patient.
33. A pharmaceutical composition according to claim 32, wherein said translocating domain is a translocating domain of a microbial protein.
34. A pharmaceutical composition according to claim 32, wherein said translocating domain is a translocating domain of a bacterial or viral protein.
35. A pharmaceutical composition according to claim 32, wherein said translocating domain is a translocating domain of a bacterial toxin, or a translocating domain of a virally expressed membrane fusion protein.
36. A pharmaceutical composition according to claim 32, wherein said translocating domain is selected from the group consisting of a translocating domain of diphtheria toxin, domain II of pseudomonas exotoxin A, a translocating domain of influenza virus haemagglutinin, a translocating domain of a fusogenic protein of Semliki Forest virus, a translocating domain of vesicular stomatitis virus glycoprotein G, a translocating domain of SER virus F protein and a translocating domain of Foamy virus envelope glycoprotein.
37. A pharmaceutical composition according to claim 32, wherein the targeting domain is a domain selected from the group consisting of Substance P, VIP, beta2 adrenoreceptor agonists, gastrin releasing peptide, and calcitonin gene related peptide.
38. A pharmaceutical composition according to claim 32, wherein said targeting domain selectively binds to a target cell selected from the group consisting of epithelial goblet cells, submucosal gland mucus-secreting cells, Clara cells, and serous cells.
39. A pharmaceutical composition according to claim 32, in a formulation for aerosol administration.
40. A method of manufacture of a compound according to claim 22, comprising:—
(a) obtaining a clostridial neurotoxin and removing or disabling the native target cell binding domain (HC) and native translocation domain (HN) of said clostridial neurotoxin to produce a modified clostridial neurotoxin or
(b) obtaining a modified clostridial neurotoxin that has had the native target cell binding domain (HC) and the native translocation domain (HN) removed or disabled; and
(c) linking the modified neurotoxin with:—
(i) a targeting domain that selectively binds the compound to a mucus secreting cell, and
(ii) a translocating domain that translocates the L-chain or L-chain fragment into the target cell.
41. A method according to claim 40, wherein said translocating domain is a translocating domain of a microbial protein.
42. A method according to claim 40, wherein said translocating domain is a translocating domain of a bacterial or viral protein.
43. A method according to claim 40, wherein said translocating domain is a translocating domain of a bacterial toxin, or a translocating domain of a virally expressed membrane fusion protein.
44. A method according to claim 40, wherein said translocating domain is selected from the group consisting of a translocating domain of diphtheria toxin, domain II of pseudomonas exotoxin A, a translocating domain of influenza virus haemagglutinin, a translocating domain of a fusogenic protein of Semliki Forest virus, a translocating domain of vesicular stomatitis virus glycoprotein G, a translocating domain of SER virus F protein and a translocating domain of Foamy virus envelope glycoprotein.
45. A method according to claim 40, wherein the targeting domain is a domain selected from the group consisting of Substance P, VIP, beta2 adrenoreceptor agonists, gastrin releasing peptide, and calcitonin gene related peptide.
46. A method according to claim 40, wherein said targeting domain selectively binds to a target cell selected from the group consisting of epithelial goblet cells, submucosal gland mucus-secreting cells, Clara cells, and serous cells.
47. A method of manufacture of a compound according to claim 22, comprising linking together:
(a) a light chain (L-chain) or L-chain fragment of a clostridial neurotoxin, which L-chain or L-chain fragment includes the active proteolytic enzyme domain of the L-chain;
(b) a translocating domain that translocates the L-chain or L-chain fragment into the target cell; and
(c) a targeting domain that selectively binds the compound to a mucus secreting cell.
48. A method according to claim 47, wherein said translocating domain is a translocating domain of a microbial protein.
49. A method according to claim 47, wherein said translocating domain is a translocating domain of a bacterial or viral protein.
50. A method according to claim 47, wherein said translocating domain is a translocating domain of a bacterial toxin, or a translocating domain of a virally expressed membrane fusion protein.
51. A method according to claim 47, wherein said translocating domain is selected from the group consisting of a translocating domain of diphtheria toxin, domain II of pseudomonas exotoxin A, a translocating domain of influenza virus haemagglutinin, a translocating domain of a fusogenic protein of Semliki Forest virus, a translocating domain of vesicular stomatitis virus glycoprotein G, a translocating domain of SER virus F protein and a translocating domain of Foamy virus envelope glycoprotein.
52. A method according to claim 47, wherein the targeting domain is a domain selected from the group consisting of Substance P, VIP, beta2 adrenoreceptor agonists, gastrin releasing peptide, and calcitonin gene related peptide.
53. A method according to claim 47, wherein said targeting domain selectively binds to a target cell selected from the group consisting of epithelial goblet cells, submucosal gland mucus-secreting cells, Clara cells, and serous cells.
54. A method according to claim 47, further comprising formulating the compound in a nasally or orally administrable composition in combination with a formulation component selected from the group consisting of an excipient, an adjuvant and a propellant, wherein said composition is for topical administration to airways of a patient.
US10/633,698 1998-08-25 2003-08-05 Methods and compounds for the treatment of mucus hypersecretion Abandoned US20040071736A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GB9818548.1 1998-08-25
GBGB9818548.1A GB9818548D0 (en) 1998-08-25 1998-08-25 Treatment of mucas hypersecretion
US09/763,669 US6632440B1 (en) 1998-08-25 1999-08-25 Methods and compounds for the treatment of mucus hypersecretion
US10/633,698 US20040071736A1 (en) 1998-08-25 2003-08-05 Methods and compounds for the treatment of mucus hypersecretion

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10/633,698 US20040071736A1 (en) 1998-08-25 2003-08-05 Methods and compounds for the treatment of mucus hypersecretion
US11/518,213 US7727538B2 (en) 1998-08-25 2006-09-11 Methods and compounds for the treatment of mucus hypersecretion
US11/798,610 US20090280066A1 (en) 1998-08-25 2007-05-15 Methods and compounds for the treatment of mucus hypersecretion
US11/806,496 US8790897B2 (en) 1998-08-25 2007-05-31 Treatment of mucus hypersecretion
US11/808,057 US20080152667A1 (en) 1998-08-25 2007-06-06 Methods and compounds for the treatment of mucus hypersecretion
US12/101,749 US20080249019A1 (en) 1998-08-25 2008-04-11 Treatment of mucus hypersecretion

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
US09763669 Continuation-In-Part
US09/763,669 Continuation-In-Part US6632440B1 (en) 1998-08-25 1999-08-25 Methods and compounds for the treatment of mucus hypersecretion
PCT/GB1999/002806 Continuation-In-Part WO2000010598A2 (en) 1998-08-25 1999-08-25 Recombinant botulinium toxin for the treatment of mucus hypersecretion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/518,213 Continuation US7727538B2 (en) 1998-08-25 2006-09-11 Methods and compounds for the treatment of mucus hypersecretion

Publications (1)

Publication Number Publication Date
US20040071736A1 true US20040071736A1 (en) 2004-04-15

Family

ID=32071324

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/633,698 Abandoned US20040071736A1 (en) 1998-08-25 2003-08-05 Methods and compounds for the treatment of mucus hypersecretion
US11/518,213 Expired - Fee Related US7727538B2 (en) 1998-08-25 2006-09-11 Methods and compounds for the treatment of mucus hypersecretion
US11/798,610 Abandoned US20090280066A1 (en) 1998-08-25 2007-05-15 Methods and compounds for the treatment of mucus hypersecretion
US11/808,057 Abandoned US20080152667A1 (en) 1998-08-25 2007-06-06 Methods and compounds for the treatment of mucus hypersecretion

Family Applications After (3)

Application Number Title Priority Date Filing Date
US11/518,213 Expired - Fee Related US7727538B2 (en) 1998-08-25 2006-09-11 Methods and compounds for the treatment of mucus hypersecretion
US11/798,610 Abandoned US20090280066A1 (en) 1998-08-25 2007-05-15 Methods and compounds for the treatment of mucus hypersecretion
US11/808,057 Abandoned US20080152667A1 (en) 1998-08-25 2007-06-06 Methods and compounds for the treatment of mucus hypersecretion

Country Status (1)

Country Link
US (4) US20040071736A1 (en)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147895A1 (en) * 1999-12-02 2003-08-07 Shone Clifford Charles Constructs for delivery of threrapeutic agents to neuronal cells
US20030166238A1 (en) * 1996-08-23 2003-09-04 Microbiological Research Authority And The Speywood Laboratory Limited Recombinant toxin fragments
US20050244435A1 (en) * 1996-08-23 2005-11-03 Shone Charles C Recombinant toxin fragments
US20050255093A1 (en) * 1998-11-05 2005-11-17 Shone Clifford C Delivery of superoxide dismutase to neuronal cells
US7052702B1 (en) 1997-10-08 2006-05-30 Health Protection Agency Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics
US20080095872A1 (en) * 2000-01-19 2008-04-24 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US20080161543A1 (en) * 2005-03-15 2008-07-03 Steward Lance E Modified Clostridial Toxins With Altered Targeting Capabilities For Clostridial Toxin Target Cells
US20080187960A1 (en) * 2004-12-01 2008-08-07 Keith Foster Non-Cytotoxic Protein Conjugates
US20080213830A1 (en) * 2004-09-01 2008-09-04 Allergan, Inc. Degradable Clostridial Toxins
US20080221012A1 (en) * 1999-08-25 2008-09-11 Allergan, Inc. Activatable Clostridial Toxins
US20080249019A1 (en) * 1998-08-25 2008-10-09 Syntaxin, Ltd. Treatment of mucus hypersecretion
US20080311170A1 (en) * 2007-04-27 2008-12-18 Indevus Pharmaceuticals, Inc. Implant device release agents and methods of using same
US20090004174A1 (en) * 2004-12-01 2009-01-01 Syntaxin Limited Fusion Proteins
US20090018081A1 (en) * 1999-08-25 2009-01-15 Allergan, Inc. Activatable clostridial toxins
US20090017071A1 (en) * 2002-02-25 2009-01-15 Allergan, Inc. Methods for treating neurogenic inflammation
US20090035822A1 (en) * 2004-12-01 2009-02-05 Keith Foster Fusion Proteins
US20090048431A1 (en) * 2004-06-30 2009-02-19 Allergan, Inc. Multivalent clostridial toxins
US20090269361A1 (en) * 1999-12-02 2009-10-29 Clifford Charles Shone Constructs for delivery of therapeutic agents to neuronal cells
US20100022751A1 (en) * 1996-08-23 2010-01-28 Syntaxin Limited Recombinant toxin fragments
US20100021522A1 (en) * 2008-06-25 2010-01-28 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other peptides
US20100041098A1 (en) * 2005-03-15 2010-02-18 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US20100247594A1 (en) * 2005-03-11 2010-09-30 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
US20110009338A1 (en) * 2005-03-11 2011-01-13 Endo Pharmaceuticals Solutions Inc. Controlled release formulations of octreotide
US20110027256A1 (en) * 2004-12-01 2011-02-03 Syntaxin Ltd. Fusion proteins
US7993656B2 (en) 2006-07-11 2011-08-09 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
US20110206745A1 (en) * 2008-06-25 2011-08-25 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
US8062652B2 (en) 2004-06-17 2011-11-22 Endo Pharmaceuticals Solutions Inc. Compositions and methods for treating precocious puberty
US20120021002A1 (en) * 2004-11-22 2012-01-26 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8518417B1 (en) 2006-07-11 2013-08-27 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
US20130251830A1 (en) * 2008-03-13 2013-09-26 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US9315549B2 (en) 2013-01-28 2016-04-19 New York University Treatment methods using atoxic neurotoxin derivatives

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
JP4838722B2 (en) 2003-10-24 2011-12-14 ゲンシア コーポレーション How to deliver the polynucleotide, and delivery composition
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
EP2034324A3 (en) * 2007-07-20 2010-06-16 Philips Electronics N.V. Sensor cartridge
US9044510B2 (en) * 2007-11-01 2015-06-02 Washington University Compositions and methods for treating pruritus
JP5728380B2 (en) * 2008-06-12 2015-06-03 シンタクシン リミテッドSyntaxin Limited Suppression of neuroendocrine disease
MX363788B (en) * 2012-11-21 2019-04-03 Ipsen Bioinnovation Ltd Methods for the manufacture of proteolytically processed polypeptides.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873346A (en) * 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792447A (en) * 1981-07-23 1988-12-20 Board Of Regents, The University Of Texas System Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
WO1996012802A1 (en) 1989-10-31 1996-05-02 Ophidian Pharmaceuticals, Inc. Vaccine and antitoxin for treatment and prevention of c. difficile disease
CA2071969A1 (en) 1989-12-22 1991-06-23 John R. Murphy Hybrid molecules having translocation region and cell-binding region
WO1992015327A1 (en) 1991-03-08 1992-09-17 Protein Design Labs, Inc. Recombinant double chain immunotoxins
WO1993004191A1 (en) 1991-08-15 1993-03-04 Neorx Corporation Noncytolytic toxin conjugates
WO1993015766A1 (en) 1992-02-10 1993-08-19 Seragen, Inc. Desensitization to specific allergens
GB9305735D0 (en) 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
DE69434008T2 (en) 1993-12-28 2005-09-22 Allergan, Inc., Irvine Botulinum toxin for the treatment of diseases associated with muscle pain
JP3497554B2 (en) 1994-03-25 2004-02-16 日本臓器製薬株式会社 New purine derivatives and pharmaceutically acceptable salts thereof
GB9411138D0 (en) 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
AU4245097A (en) 1996-08-28 1998-03-19 Ophidian Pharmaceuticals, Inc. Multivalent vaccine for (clostridium botulinum) neurotoxin
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
WO1997013410A1 (en) 1995-10-13 1997-04-17 Boston Medical Center Corporation Hybrid molecules containing amidated polypeptide binding ligands
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US5760149A (en) 1996-08-23 1998-06-02 Elf Atochem North America, Inc. Poly(monoperoxycarbonates)
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
DE19735105A1 (en) 1997-08-13 1999-03-04 Univ Albert Ludwigs Freiburg New fusion protein
GB9721189D0 (en) * 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
HU0103601A3 (en) 1998-05-13 2004-06-28 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof
DE69934337T2 (en) 1998-07-22 2007-05-24 Osprey Pharmaceuticals Ltd., Calgary Conjugates for the treatment of inflammatory diseases and tissue damage assozierter
GB9818548D0 (en) * 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US20080032931A1 (en) * 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
US20090018081A1 (en) * 1999-08-25 2009-01-15 Allergan, Inc. Activatable clostridial toxins
US7740868B2 (en) * 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
BR0012759A (en) * 1999-08-25 2002-04-02 Allergan Sales Inc activatable recombinant neurotoxin
US7368532B2 (en) * 1999-12-02 2008-05-06 Syntaxin Limited Constructs for delivery of therapeutic agents to neuronal cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873346A (en) * 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin

Cited By (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017134B2 (en) 1996-08-23 2011-09-13 Syntaxin Limited Recombinant toxin fragments
US20030166238A1 (en) * 1996-08-23 2003-09-04 Microbiological Research Authority And The Speywood Laboratory Limited Recombinant toxin fragments
US20050244435A1 (en) * 1996-08-23 2005-11-03 Shone Charles C Recombinant toxin fragments
US8012491B2 (en) 1996-08-23 2011-09-06 Syntaxin, Ltd. Recombinant toxin fragments
US20090148888A1 (en) * 1996-08-23 2009-06-11 Syntaxin Limited Recombinant toxin fragments
US7674470B2 (en) 1996-08-23 2010-03-09 Health Protection Agency Recombinant toxin fragments
US20070184070A1 (en) * 1996-08-23 2007-08-09 Shone Clifford C Recombinant toxin fragments
US20070248626A1 (en) * 1996-08-23 2007-10-25 The Health Protection Agency Recombinant toxin fragments
US20090246827A1 (en) * 1996-08-23 2009-10-01 Syntaxin Limited Recombinant toxin fragments
US20100022751A1 (en) * 1996-08-23 2010-01-28 Syntaxin Limited Recombinant toxin fragments
US7897158B2 (en) 1996-08-23 2011-03-01 Syntaxin, Ltd Recombinant toxin fragments
US8454976B2 (en) 1996-08-23 2013-06-04 Syntaxin Limited Recombinant toxin fragments
US20090274708A1 (en) * 1996-08-23 2009-11-05 Health Protection Agency Recombinant Toxin Fragments
US8012479B2 (en) 1996-08-23 2011-09-06 Health Protection Agency Recombinant toxin fragments
US7052702B1 (en) 1997-10-08 2006-05-30 Health Protection Agency Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics
US7452543B2 (en) 1997-10-08 2008-11-18 Syntaxin Ltd. Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics
US20080249019A1 (en) * 1998-08-25 2008-10-09 Syntaxin, Ltd. Treatment of mucus hypersecretion
US20050255093A1 (en) * 1998-11-05 2005-11-17 Shone Clifford C Delivery of superoxide dismutase to neuronal cells
US7470661B2 (en) 1998-11-05 2008-12-30 Syntaxin Limited Delivery of superoxide dismutase to neuronal cells
US20090081730A1 (en) * 1999-08-25 2009-03-26 Allergan, Inc. Activatable recombinant neurotoxins
US8003351B2 (en) 1999-08-25 2011-08-23 Allergan, Inc. Activatable recombinant neurotoxins
US20080311622A1 (en) * 1999-08-25 2008-12-18 Allergan, Inc. Activatable recombinant neurotoxins
US20090005313A1 (en) * 1999-08-25 2009-01-01 Steward Lance E Activatable clostridial toxins
US20090004224A1 (en) * 1999-08-25 2009-01-01 Allergan, Inc. Activatable clostridial toxins
US8119370B2 (en) 1999-08-25 2012-02-21 Allergan, Inc. Activatable recombinant neurotoxins
US8211671B2 (en) 1999-08-25 2012-07-03 Allergan, Inc. Activatable recombinant neurotoxins
US20090018081A1 (en) * 1999-08-25 2009-01-15 Allergan, Inc. Activatable clostridial toxins
US8273358B2 (en) 1999-08-25 2012-09-25 Allergan, Inc. Activatable clostridial toxins
US8071110B2 (en) 1999-08-25 2011-12-06 Allergan, Inc. Activatable clostridial toxins
US7985411B2 (en) 1999-08-25 2011-07-26 Allergan, Inc. Activatable recombinant neurotoxins
US7959933B2 (en) 1999-08-25 2011-06-14 Allergan, Inc. Activatable recombinant neurotoxins
US20090042270A1 (en) * 1999-08-25 2009-02-12 Allergan, Inc. Activatable recombinant neurotoxins
US7897157B2 (en) 1999-08-25 2011-03-01 Allergan, Inc. Activatable clostridial toxins
US20090087458A1 (en) * 1999-08-25 2009-04-02 Allergan, Inc. Activatable recombinant neurotoxins
US20090069238A1 (en) * 1999-08-25 2009-03-12 Allergan, Inc. Activatable clostridial toxins
US20090030182A1 (en) * 1999-08-25 2009-01-29 Allergan, Inc. Activatable recombinant neurotoxins
US20080221012A1 (en) * 1999-08-25 2008-09-11 Allergan, Inc. Activatable Clostridial Toxins
US20090269361A1 (en) * 1999-12-02 2009-10-29 Clifford Charles Shone Constructs for delivery of therapeutic agents to neuronal cells
US7368532B2 (en) 1999-12-02 2008-05-06 Syntaxin Limited Constructs for delivery of therapeutic agents to neuronal cells
US20030147895A1 (en) * 1999-12-02 2003-08-07 Shone Clifford Charles Constructs for delivery of threrapeutic agents to neuronal cells
US7736659B2 (en) 2000-01-19 2010-06-15 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7833535B2 (en) 2000-01-19 2010-11-16 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7622127B2 (en) 2000-01-19 2009-11-24 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US8017131B2 (en) 2000-01-19 2011-09-13 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US20080213311A1 (en) * 2000-01-19 2008-09-04 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US20090010967A1 (en) * 2000-01-19 2009-01-08 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US20080317782A1 (en) * 2000-01-19 2008-12-25 Stephen Donovan Clostridial toxin derivatives and methods for treating pain
US20090042799A1 (en) * 2000-01-19 2009-02-12 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US20080095872A1 (en) * 2000-01-19 2008-04-24 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7704512B2 (en) 2000-01-19 2010-04-27 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7780968B2 (en) 2000-01-19 2010-08-24 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US20080317783A1 (en) * 2000-01-19 2008-12-25 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US20090017071A1 (en) * 2002-02-25 2009-01-15 Allergan, Inc. Methods for treating neurogenic inflammation
US9006395B2 (en) 2002-09-12 2015-04-14 The Secretary Of State For Health Recombinant toxin fragments
US20110028691A1 (en) * 2002-09-12 2011-02-03 The Health Protection Agency Recombinant toxin fragments
US20060110410A1 (en) * 2002-09-12 2006-05-25 Shone Clifford C Recombinant toxin fragments
US8062652B2 (en) 2004-06-17 2011-11-22 Endo Pharmaceuticals Solutions Inc. Compositions and methods for treating precocious puberty
US20090048431A1 (en) * 2004-06-30 2009-02-19 Allergan, Inc. Multivalent clostridial toxins
US7811584B2 (en) 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US7998489B2 (en) 2004-09-01 2011-08-16 Allergan, Inc. Degradable clostridial toxins
US7892565B2 (en) 2004-09-01 2011-02-22 Allergan, Inc. Degradable clostridial toxins
US20080213830A1 (en) * 2004-09-01 2008-09-04 Allergan, Inc. Degradable Clostridial Toxins
US20090023901A1 (en) * 2004-09-01 2009-01-22 Steward Lance E Degradable Clostridial Toxins
US20120021002A1 (en) * 2004-11-22 2012-01-26 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
US8865186B2 (en) * 2004-11-22 2014-10-21 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
US8399401B2 (en) 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
US8124074B2 (en) 2004-12-01 2012-02-28 Syntaxin Limited Fusion proteins
US20110027256A1 (en) * 2004-12-01 2011-02-03 Syntaxin Ltd. Fusion proteins
US8956847B2 (en) 2004-12-01 2015-02-17 Syntaxin Limited Fusion proteins
US8940870B2 (en) 2004-12-01 2015-01-27 Syntaxin, Ltd. Fusion proteins
US7659092B2 (en) 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
US20110177053A1 (en) * 2004-12-01 2011-07-21 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US20090162341A1 (en) * 2004-12-01 2009-06-25 Keith Foster Non-Cytotoxic Protein Conjugates
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US9474807B2 (en) 2004-12-01 2016-10-25 Ipsen Bioinnovation Limited Non-cytotoxic protein conjugates
US20090035822A1 (en) * 2004-12-01 2009-02-05 Keith Foster Fusion Proteins
US8067200B2 (en) 2004-12-01 2011-11-29 Syntaxin Ltd. Fusion proteins
US20100247509A1 (en) * 2004-12-01 2010-09-30 Keith Foster Fusion Proteins
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US9012195B2 (en) 2004-12-01 2015-04-21 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US20090004174A1 (en) * 2004-12-01 2009-01-01 Syntaxin Limited Fusion Proteins
US8399400B2 (en) 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
US8187834B2 (en) 2004-12-01 2012-05-29 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US20080187960A1 (en) * 2004-12-01 2008-08-07 Keith Foster Non-Cytotoxic Protein Conjugates
US9139635B2 (en) 2004-12-01 2015-09-22 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8372615B2 (en) 2004-12-01 2013-02-12 Syntaxin, Limited Fusion proteins
US7658933B2 (en) 2004-12-01 2010-02-09 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US20100247594A1 (en) * 2005-03-11 2010-09-30 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
US20110009338A1 (en) * 2005-03-11 2011-01-13 Endo Pharmaceuticals Solutions Inc. Controlled release formulations of octreotide
US8507432B2 (en) 2005-03-11 2013-08-13 Endo Pharmaceuticals Solutions Inc. Controlled release formulations of octreotide
US20080161543A1 (en) * 2005-03-15 2008-07-03 Steward Lance E Modified Clostridial Toxins With Altered Targeting Capabilities For Clostridial Toxin Target Cells
US8021859B2 (en) 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US8460682B2 (en) 2005-03-15 2013-06-11 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US20100041098A1 (en) * 2005-03-15 2010-02-18 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US8052979B2 (en) 2005-03-15 2011-11-08 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US7993656B2 (en) 2006-07-11 2011-08-09 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
US8518417B1 (en) 2006-07-11 2013-08-27 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
US20080311170A1 (en) * 2007-04-27 2008-12-18 Indevus Pharmaceuticals, Inc. Implant device release agents and methods of using same
US9120249B2 (en) 2007-04-27 2015-09-01 Endo Pharmaceuticals Solutions Inc. Implant device release agents and methods of using same
US20130251830A1 (en) * 2008-03-13 2013-09-26 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US20100021522A1 (en) * 2008-06-25 2010-01-28 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other peptides
US20110206745A1 (en) * 2008-06-25 2011-08-25 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
US20100292144A1 (en) * 2008-06-25 2010-11-18 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other peptides
US9072786B2 (en) 2008-06-25 2015-07-07 Endo Pharmaceuticals Solutions Inc. Method of manufacturing an implantable device
US8071537B2 (en) 2008-06-25 2011-12-06 Endo Pharmaceuticals Solutions Inc. Implantable device for the sustained release of a polypeptide
US8475820B2 (en) 2008-06-25 2013-07-02 Endo Pharmaceuticals Solutions Inc. Method of manufacturing an implantable device
US8383577B2 (en) 2008-06-25 2013-02-26 Endo Pharmaceuticals Solutions, Inc. Octreotide implant having a release agent
US9315549B2 (en) 2013-01-28 2016-04-19 New York University Treatment methods using atoxic neurotoxin derivatives

Also Published As

Publication number Publication date
US20090280066A1 (en) 2009-11-12
US20070010447A1 (en) 2007-01-11
US20080152667A1 (en) 2008-06-26
US7727538B2 (en) 2010-06-01

Similar Documents

Publication Publication Date Title
JP4557426B2 (en) Stable liquid formulations of botulinum toxin
US8071110B2 (en) Activatable clostridial toxins
Yamasaki et al. Botulinum neurotoxin type G proteolyses the Ala81-Ala82 bond of rat synaptobrevin 2
ES2198750T3 (en) Conjugates of lectins that bind galactose and clostridial neurotoxins as analgesics.
US4892827A (en) Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
ES2225876T3 (en) Botulinum Toxin derivatives able to modify the functions of peripheral sensory afferents.
CA2191754C (en) Modification of clostridial toxins for use as transport proteins
AU2002228684B9 (en) Neurotoxins with enhanced target specificity
US7138127B1 (en) Clostridial toxin derivatives and methods for treating pain
Hwang et al. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli
US7785856B2 (en) Acid alpha-glucosidase and fragments thereof
US20080025994A1 (en) Methods and compositions for the treatment of pancreatitis
US6461617B1 (en) Recombinant toxin fragments
US20080032931A1 (en) Activatable clostridial toxins
US9072736B2 (en) Treatment of pain
AU752086B2 (en) Mutagenized il13-based chimeric molecules
ES2431119T3 (en) Conjugates not cytotoxic proteins
CA2498502C (en) Recombinant clostridial toxin fragments with proteolytic activation
US7705125B2 (en) Leucine-based motif and Clostridial neurotoxins
US20020177545A1 (en) Compositions and methods for treating gonadotrophin related illnesses
JP5833039B2 (en) Transport proteins used to introduce the compound into neurons
US7514088B2 (en) Multivalent Clostridial toxin derivatives and methods of their use
Li et al. Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells
EP1165114B1 (en) Use of a lectin or conjugates for modulation of c-fibre activity
CA2593520C (en) Recombinant expression of proteins in a disulfide-bridged, two-chain form

Legal Events

Date Code Title Description
AS Assignment

Owner name: HEALTH PROTECTION AGENCY, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:QUINN, CONRAD PADRAIG;FOSTER, KEITH ALAN;CHADDOCK, JOHN;REEL/FRAME:014741/0329

Effective date: 20030925

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: SYNTAXIN LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HEALTH PROTECTION AGENCY;REEL/FRAME:020077/0344

Effective date: 20070808